PLOS Bio:“时钟疗法”——这种肿瘤抑制剂的发现将变革现有癌症疗法!

2017-12-08 佚名 medicalxpress

我们的身体有一个内部生物或“昼夜节律”的时钟,每天循环,并与太阳时间同步。在小鼠中进行的新研究表明,它可以帮助抑制癌症。这项由德国柏林Charité医科大学的AngelaRelógio博士及其同事于12月7日在开放获取期刊PLOS Biology上发表的研究假设,由于其调节的分子时间依赖过程的范围包括代谢,DNA修复和细胞周期,昼夜节律钟有潜力充当肿瘤抑制剂。

我们的身体有一个内部生物或“昼夜节律”的时钟,每天循环,并与太阳时间同步。在小鼠中进行的新研究表明,它可以帮助抑制癌症。这项由德国柏林Charité医科大学的AngelaRelógio博士及其同事于12月7日在开放获取期刊PLOS Biology上发表的研究假设,由于其调节的分子时间依赖过程的范围包括代谢,DNA修复和细胞周期,昼夜节律钟有潜力充当肿瘤抑制剂。

昼夜节律时钟与环境明暗周期同步,有助于协调代谢和行为模式,如休息和活动的日常周期。包括癌症在内的许多疾病都可能扰乱时钟,导致它横行。然而,当我们体内的细胞繁殖时,它们会遵循一个不同的计划,称为细胞周期,在细胞周期结束时,通过细胞分裂产生两个子细胞。许多癌症涉及功能失调或活动过度的细胞周期,这使得肿瘤细胞无法控制地繁殖。

研究小组发现,当他们在大约四分之一的人类肿瘤和两种称为INK4a和ARF的蛋白质(它们能够抑制癌症)中扰乱一种叫做RAS的蛋白质时,发现了生物钟和细胞周期。他们表明,已知控制细胞周期的RAS也控制昼夜节律,并通过INK4A和ARF对生物钟发挥其作用。他们的工作突出了生物钟作为细胞命运决策的调节器的重要作用,并进一步加强了生物钟作为防癌机制的功能。

Relógio在葡萄牙语中的意思是“钟”,他说:“根据我们的研究结果,在我们看来,这个时钟很可能是一种肿瘤抑制剂,对于癌细胞来说,它有利于规避昼夜节律。不能停止想知道昼夜节律时间是否应该被列为癌症的下一个潜在标志。”

Relógio及其同事的研究结果表明,复杂性的一个新层 - 内部时间 - 可能与癌症治疗有关,最近的研究提出使用时间疗法,其中睡眠和清醒时间被调整,试图重置病人的生物钟。鉴于此处所述的新发现和迄今为止发表的时间疗法研究,我们可能需要重新考虑癌症治疗,包括内部时间因素,以达到最佳治疗效果。

原始出处:

Rukeia El-Athman, Nikolai N. Genov, Jeannine Mazuch, et.al. The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity. PLOS Biology

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752906, encodeId=62921e52906ac, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Wed Sep 19 19:20:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851592, encodeId=09b5185159222, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 14 10:20:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917824, encodeId=b61e191e82413, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 13 04:20:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809142, encodeId=01f8180914286, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Mon Sep 24 18:20:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268175, encodeId=baed2681e5ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Sat Dec 09 21:20:47 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2018-09-19 mnda
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752906, encodeId=62921e52906ac, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Wed Sep 19 19:20:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851592, encodeId=09b5185159222, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 14 10:20:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917824, encodeId=b61e191e82413, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 13 04:20:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809142, encodeId=01f8180914286, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Mon Sep 24 18:20:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268175, encodeId=baed2681e5ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Sat Dec 09 21:20:47 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2018-07-14 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752906, encodeId=62921e52906ac, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Wed Sep 19 19:20:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851592, encodeId=09b5185159222, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 14 10:20:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917824, encodeId=b61e191e82413, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 13 04:20:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809142, encodeId=01f8180914286, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Mon Sep 24 18:20:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268175, encodeId=baed2681e5ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Sat Dec 09 21:20:47 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2018-04-13 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1752906, encodeId=62921e52906ac, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Wed Sep 19 19:20:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851592, encodeId=09b5185159222, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 14 10:20:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917824, encodeId=b61e191e82413, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 13 04:20:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809142, encodeId=01f8180914286, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Mon Sep 24 18:20:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268175, encodeId=baed2681e5ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Sat Dec 09 21:20:47 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1752906, encodeId=62921e52906ac, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Wed Sep 19 19:20:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851592, encodeId=09b5185159222, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 14 10:20:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917824, encodeId=b61e191e82413, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Apr 13 04:20:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809142, encodeId=01f8180914286, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Mon Sep 24 18:20:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268175, encodeId=baed2681e5ec, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KiblTyxD95ExbzUoCVcRuhPibXboL28wicFMTXUhCA0RWCyQZYC5Na3ap7CxjialMkB50VEJ0XToQQTC/0, createdBy=470c1945776, createdName=方舒, createdTime=Sat Dec 09 21:20:47 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2017-12-09 方舒

    学习

    0

相关资讯

人之将死其言也善,肿瘤专家临终遗言:让癌症康复**不是药物

华益慰 (1933年-2006年):原北京军区总医院普外科主任、2006年“感动中国”年度人物。中华医学会外科学会常务委员,享受政府特殊津贴。

Lancet Diabetes Endo:糖尿病、高体重指数与多种肿瘤风险

研究发现,因糖尿病以及高体重指数导致的肿瘤患者数量相当庞大且发病率逐年上升

恶性肿瘤原发病灶不明?上海肿瘤医院专设中心为患者追根溯源

门诊里,经常会碰见很多患者拿着“多原发”或“原发病灶不明”的肿瘤病理诊断报告慌然失措,面对这些“看不见的肿瘤”,多数临床医生也无法给予及时精确的诊断。门诊里,经常会碰见很多患者拿着“多原发”或“原发病灶不明”的肿瘤病理诊断报告慌然失措,面对这些“看不见的肿瘤”,多数临床医生也无法给予及时精确的诊断。如何服务这部分患者?记者11月29日从复旦大学附属肿瘤医院获悉,为了让这部分患者能在短时间内得到精准

肿瘤性钙盐沉着症1例

患者,女,53岁。

骶骨肿瘤:手术方法虽多但问题不少

骶骨肿瘤的手术方法虽多,但问题不少,如大出血、大小便及性功能问题。如何保证手术安全和患者的生活质量?请看以下病例——

肾上腺原始神经外胚层肿瘤1例

综合国内外文献报道,原始神经外胚层肿瘤的特点是病史较短,病势凶险,肿瘤极具浸润性,常表现为局部复发和远处转移,死亡率高。手术联合放、化疗等的综合治疗可提高生存率,但预后不佳。以下病例即为肾上腺原始神经外胚层肿瘤1例,具体如下——